NAMS
NewAmsterdam Pharma Company N.V.
$20.47
+3.23% 2026-10-19
Healthcare
NAMSSPY
1W
-3.7%
1M
-9.0%
3M
-31.0%
6M
-39.5%
YTD
-41.6%
1Y
-43.8%
Grades vs sector
Momentumno data–
Momentum
no data
Percentile within its GICS sector across the S&P 1500.
Growthno data–
Growth
no data
Percentile within its GICS sector across the S&P 1500.
Valueno data–
Value
no data
Percentile within its GICS sector across the S&P 1500.
Profitabilityno data–
Profitability
no data
Percentile within its GICS sector across the S&P 1500.
Revisionsno data–
Revisions
no data
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 3 live models right now.
Momentum Top 15
not ranked (outside this model's universe or screens)
Quality Growthnot ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
Key stats
Market cap$2.4B
P/E (trailing)–
P/E (forward)-13.4
52-week range19.58 – 42.20
Revenue growth (YoY, latest qtr)-80.7%
Dividend yield0.00%
Analyst consensusStrong Buy (15)
Mean price target$49.81 (+143%)
Valuation & fundamentals
Bottom line
No cash-flow valuation
Model read-out from the numbers below, not advice. Score +0 (DCF counts double).
▼Piotroski F-score3/9
▲Altman Z17.8 (safe)
▲Analyst target+143% (15 analysts)
Discounted cash flow
Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Trailing free cash flow is zero or negative, so there's no growth rate to solve for. The price is betting on a turnaround to positive cash flow.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.10 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $-1.53 vs trailing $-2.16. Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Gross margin
–
Operating margin
-3432.2%
FCF margin
-2014.6%
Net margin
-3644.2%
Return on equity
-41.1%
Return on invested capital
–
Net debt / EBITDA
–
Current ratio
9.0×
Interest cover
-851.6×
Cash conversion (OCF/NI)
–
Piotroski F-score 3/9 · last two fiscal years
✗ Positive net income✗ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✗ No share dilution✗ Gross margin improved✗ Asset turnover improved
Altman Z-score 17.8 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Mean target
$50
+143%
Analysts
15
Strong Buy
Range
$38–$59
low – high
● price · ◆ mean target
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $22.5M | $-203.8M | $-147.8M |
| 2024 | $45.6M | $-241.6M | $-158.6M |
| 2023 | $14.1M | $-176.9M | $-141.2M |
| 2022 | $102.7M | $-22.6M | $10.7M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR -39.7%.
Earnings
Next report: 2026-11-04 · before open · EPS est -0.44
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | -0.43 | -0.45 | -5.7% |
| 2026-05-07 | -0.41 | -0.34 | +16.5% |
| 2026-02-18 | -0.37 | -0.53 | -45.3% |
| 2025-11-05 | -0.34 | -0.53 | -54.0% |
| 2025-08-06 | -0.43 | -0.13 | +69.8% |
| 2025-05-08 | -0.44 | -0.30 | +30.9% |
| 2025-02-26 | -0.47 | -0.90 | -94.0% |
| 2024-11-06 | -0.45 | -0.16 | +63.3% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $3.7M | -80.7% |
| 2026-03-31 | $3.0M | – |
| 2025-12-31 | $32.0K | – |
| 2025-09-30 | $348.0K | – |
| 2025-06-30 | $19.1M | – |
Analyst actions
RBC Capital
PT $42
2026-10-05 · main
Outperform → OutperformPT $42
HC Wainwright & Co.
PT $52
2026-09-08 · reit
Buy → BuyPT $52
RBC Capital
PT $50
2026-08-06 · main
Outperform → OutperformPT $50
RBC Capital
PT $51
2026-06-30 · main
Outperform → OutperformPT $51
Guggenheim
PT $45
2026-02-19 · main
Buy → BuyPT $45
Needham
PT $48
2026-02-18 · main
Buy → BuyPT $48
Insider trades
Kastelein Johannes Jacob Pieter
$1.3M
Director, Chief Scientific Officer · 2026-09-30
SELL$1.3M
Davidson Michael H.
$226.5K
Director, Chief Executive Officer · 2026-09-14
BUY$226.5K
Smither John W
$40.5K
Director · 2026-09-04
SELL$40.5K
Kastelein Johannes Jacob Pieter
$3.4M
Director, Chief Scientific Officer · 2026-08-24
SELL$3.4M
Kooij Louise Frederika
$2.1M
Chief Accounting Officer · 2026-07-20
SELL$2.1M
Kooij Louise Frederika
$990.0K
Chief Accounting Officer · 2026-07-20
SELL$990.0K
Kooij Louise Frederika
$92.4K
Chief Accounting Officer · 2026-07-20
SELL$92.4K
None
–
None · None
SELL–
News
Does NewAmsterdam Pharma’s (NAMS) Genotype-Targeted SPINOZA Trial Reframe Obicetrapib’s Long-Term Alzheimer’s Strategy?
Simply Wall St. · Oct 13
NewAmsterdam PREVAIL Interim Faces 'Considerable' Risk, RBC Says
MT Newswires · Oct 05
RBC Cuts Price Target on NewAmsterdam Pharma to $42 From $50, Keeps Outperform, Speculative Risk
MT Newswires · Oct 05
Group 1 Automotive and 4 More Stocks See Action From Activist Investors
Barrons.com · Oct 02
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 02
NewAmsterdam Pharma Doses First Participant in Phase 2b Trial for Preclinical Alzheimer's Disease
MT Newswires · Sep 29
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
GlobeNewswire · Sep 29
NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?
Insider Monkey · Sep 22
Stats refreshed 2026-10-19 19:02:22 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau